When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer (NSCLC), the Swiss pharma played up signs that it said …
A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a …
AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the second of two Phase 3 …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
